Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584775 | 0.83 | CHRNA4 (0.54) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22874982 | 0.79 | CHRNA4 (0.51) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20935043 | 0.76 | CHRNA4 (0.48) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20152893 | 0.75 | RIPK1 (0.55) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14443021 | 0.74 | ALDH1A1 (0.68) | — | |
| SCHEMBL18255212 | 0.73 | RIPK1 (0.59) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL28473078 | 0.72 | CHRNA4 (0.52) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20138338 | 0.71 | RIPK1 (0.52) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21062061 | 0.71 | CHRNA4 (0.62) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21095630 | 0.71 | CHRNA4 (0.62) | CHRNA4CHRNA7CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115417-A1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-22 | — | — | US | claimed |
| EP-3724324-A1 | CARBOXYESTERASE BIOCATALYSTS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | claimed |
| WO-2019116311-A1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | claimed |
| US-12331327-B2 | Carboxyesterase biocatalysts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| EP-3724324-B1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| EP-4471137-A2 | CARBOXYESTERASE BIOCATALYSTS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2024-12-04 | — | — | EP | disclosed |
| US-20230193227-A1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230193227-A1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230193227-A1 | CARBOXYESTERASE BIOCATALYSTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| US-11535833-B2 | Carboxyesterase biocatalysts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-12-27 | — | — | US | disclosed |
| WO-2018192864-A1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-25 | — | — | WO | disclosed |
| US-20180155334-A1 | NOVEL PROCESSES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180155334-A1 | NOVEL PROCESSES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180155334-A1 | NOVEL PROCESSES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-07 | — | — | US | disclosed |
| EP-3303329-A1 | PROCESSES TO MAKE INDAZOLE DERIVATIVES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018029126-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018029126-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | WO | disclosed |
| WO-2016193255-A1 | PROCESSES TO MAKE INDAZOLE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193255-A1 | PROCESSES TO MAKE INDAZOLE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155334-A1 | NOVEL PROCESSES | CYP4A11, CYP4F11, CYP4F3 | CHRNA4 2633/4885CHRNA7 4460/4885CHRNB2 3933/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRNA4 1135/4885CHRNA7 1113/4885CHRNB2 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.